Epistatic connectivity among HCV genomic sites as a genetic marker of interferon resistance

Antiviral Therapy

Volumn 17, Issue 7 PARTB, 2012, Pages 1471-1475

  Lara, James ^a   Khudyakov, Yury ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORE PROTEIN; INTERFERON; NONSTRUCTURAL PROTEIN 2; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5B; PROTEIN KINASE R; RIBAVIRIN; RNA ACTIVATED PROTEIN KINASE R; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTIVIRAL RESISTANCE; DNA POLYMORPHISM; DRUG MECHANISM; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC EPISTASIS; GENETIC HETEROGENEITY; GENETIC MARKER; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HEPATITIS C; HOST SELECTION; HUMAN; IMMUNOREGULATION; INNATE IMMUNITY; MOLECULAR EVOLUTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN LOCALIZATION; REVIEW; TREATMENT OUTCOME; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS MUTATION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; BIOLOGICAL EVOLUTION; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; EPISTASIS, GENETIC; GENETIC MARKERS; GENETIC VARIATION; GENOME, VIRAL; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERONS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84871984459     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2478     Document Type: Review

References (50)

1. Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM. Structural biology of hepatitis C virus. Hepatology 2004; 39:5-19. (Pubitemid 38461460)
2. Choo QL, Weiner AJ, Overby LR, Kuo G, Houghton M, Bradley DW. Hepatitis C virus: the major causative agent of viral non-A, non-B Hepatitis. Br Med Bull 1990; 46:423-441. (Pubitemid 20158079)
3. WHO. Hepatitis C: global prevalence. Geneva:World Health Organization 1997; pp. 341-344.
4. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
5. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49:1335-1374.
6. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361:580-593.
7. Jensen DM. A new era of hepatitis C therapy begins. N Engl J Med 2011; 364:1272-1274.
8. Forestier N, Zeuzem S. Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders. Liver Int 2012; 32 Suppl 1:44-50.
9. Sadler AJ, Williams BR. Interferon-inducible antiviral effectors. Nat Rev Immunol 2008; 8:559-568. (Pubitemid 351913674)
10. Magiorkinis G, Magiorkinis E, Paraskevis D, et al. The global spread of hepatitis C virus 1a and 1b: a phylodynamic and phylogeographic analysis. PLoS Med 2009; 6:e1000198.
11. Hadziyannis SJ, Sette H, Jr., Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-355.
12. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461:798-801.
13. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399-401.
14. Tillmann HL, Thompson AJ, Patel K, et al. A polymorphism near IL28B is associated with spontaneous clearance, of acute hepatitis C virus and jaundice. Gastroenterology 2010; 139:1586-1592.
15. Asselah T, Estrabaud E, Bieche I, et al. Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int 2010; 30:1259-1269.
16. Le Guillou-Guillemette H, Vallet S, Gaudy-Graffin C, et al. Genetic diversity of the hepatitis C virus: impact and issues in the antiviral therapy. World J Gastroenterol 2007;13:2416-2426. (Pubitemid 46929496)
17. Jiang D, Guo H, Xu C, et al. Identification of three interferon-inducible cellular enzymes that inhibit the replication of hepatitis C virus. J Virol 2008; 82:1665-1678. (Pubitemid 351206918)
18. Melén K, Keskinen P, Lehtonen A, Julkunen I. Interferon-induced gene expression and signaling in human hepatoma cell lines. J Hepatol. 2000; 33:764-772.
19. Contreras AM, Hiasa Y, He W, Terella A, Schmidt EV, Chung RT. Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. J Virol 2002; 76:8505-8517. (Pubitemid 34864045)
20. Zhou S, Liu R, Baroudy BM, Malcolm BA, Reyes GR. The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology 2003; 310:333-342. (Pubitemid 37492916)
21. Goswami BB, Crea R, Van Boom JH, Sharma OK. 2′-5′-Linked oligo(adenylic acid) and its analogs. A new class of inhibitors of mRNA methylation. J Biol Chem 1982; 257:6867-6870. (Pubitemid 12022280)
22. Tam RC, Pai B, Bard J, et al. Ribavirin polarizes human T cell responses towards a type 1 cytokine profile. J Hepatol 1999; 30:376-382. (Pubitemid 29113223)
23. Feld JJ, Lutchman GA, Heller T, et al. Ribavirin improves early responses to peginterferon through improved interferon signaling. Gastroenterology 2010; 139:154-162.
24. Feld JJ, Nanda S, Huang Y, et al. Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology 2007; 46:1548-1563. (Pubitemid 350155537)
25. Gale MJ, Jr., Korth MJ, Tang NM, et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 1997; 230:217-227. (Pubitemid 27211852)
26. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MM. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 1999; 285:107-110. (Pubitemid 29307576)
27. Abid K, Quadri R, Negro F. Hepatitis C virus, the E2 envelope protein, and alpha-interferon resistance. Science 2000; 287:1555.
28. Polyak SJ, Nousbaum JB, Larson AM, Cotler S, Carithers RL, Jr., Gretch DR. The protein kinase-interacting domain in the hepatitis C virus envelope glycoprotein-2 gene is highly conserved in genotype 1-infected patients treated with interferon. J Infect Dis 2000; 182:397-404. (Pubitemid 30654821)
29. Enomoto N, Sakuma I, Asahina Y, et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 1995; 96:224-230.
30. Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334:77-81. (Pubitemid 26017933)
31. Pascu M, Martus P, Hohne M, et al. Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5AISDR: a meta-analysis focused on geographical differences. Gut 2004; 53:1345-1351. (Pubitemid 39120125)
32. Bagaglio S, Bruno R, Lodrini S, et al. Genetic heterogeneity of hepatitis C virus (HCV) in clinical strains of HIV positive and HIV negative patients chronically infected with HCV genotype 3a. J Biol Regul Homeost Agents 2003; 17:153-161. (Pubitemid 37220847)
33. Murakami T, Enomoto N, Kurosaki M, Izumi N, Marumo F, Sato C. Mutations in nonstructural protein 5A gene and response to interferon in hepatitis C virus genotype 2 infection. Hepatology 1999; 30:1045-1053. (Pubitemid 29458295)
34. Castelain S, Khorsi H, Roussel J, et al. Variability of the nonstructural 5A protein of hepatitis C virus type 3a isolates and relation to interferon sensitivity. J Infect Dis 2002; 185:573-583. (Pubitemid 34171461)
35. Cannon NA, Donlin MJ, Fan X, Aurora R, Tavis JE. Hepatitis C virus diversity and evolution in the full open-reading frame during antiviral therapy. PLoS ONE 2008; 3:e2123.
36. El-Shamy A, Shoji I, Saito T, et al. Sequence heterogeneity of NS5A and core proteins of hepatitis C virus and virological responses to pegylated-interferon/ribavirin combination therapy. Microbiol Immunol 2011; 55:418-426.
37. Enomoto N, Maekawa S. HCV genetic elements determining the early response to peginterferon and ribavirin therapy. Intervirology 2010; 53:66-69.
38. Kumthip K, Pantip C, Chusri P, et al. Correlation between mutations in the core and NS5A genes of hepatitis C virus genotypes 1a, 1b, 3a, 3b, 6f and the response to pegylated interferon and ribavirin combination therapy. J Viral Hepat 2011; 18:e117-e125.
39. Mihm U, Grigorian N, Christopher W, et al. Amino acid variations in hepatitis C virus C p7 and sensitivity to antiviral combination therapy with amantadine in chronic hepatitis C. Antivir Ther 2006; 11:507-519. (Pubitemid 44024859)
40. Hino K, Yamaguchi Y, Fujiwara D, et al. Hepatitis C virus quasispecies and response to interferon therapy in patients with chronic hepatitis C: a prospective study. J Viral Hepat 2000; 7:36-42. (Pubitemid 30139850)
41. Wohnsland A, Hofmann WP, Sarrazin C. Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev 2007; 20:23-38. (Pubitemid 46167766)
42. Cannon NA, Donlin MJ, Fan X, Aurora R, Tavis JE. Hepatitis C virus diversity and evolution in the full open-reading frame during antiviral therapy. PLoS ONE 2008; 3:e2123.
43. Bonhoeffer S, Chappey C, Parkin NT, Whitcomb JM, Petropoulos CJ. Evidence for positive epistasis in HIV-1. Science 2004; 306:1547-1550. (Pubitemid 39564948)
44. Sanjuán R, Moya A, Elena SF. The contribution of epistasis to the architecture of fitness in an RNA virus. Proc Natl Acad Sci U S A 2004; 101:15376-15379. (Pubitemid 39441549)
45. Khudyakov Y. Coevolution and HBV drug resistance. Antivir Ther 2010; 15:505-515.
46. Yi M, Ma Y, Yates J, Lemon SM. Compensatory mutations in E1, p7, NS2, and NS3 enhance yields of cell culture-infectious intergenotypic chimeric hepatitis C virus. J Virol 2007; 81:629-638. (Pubitemid 46067890)
47. Campo DS, Dimitrova Z, Mitchell RJ, Lara J, Khudyakov Y. Coordinated evolution of the hepatitis C virus. Proc Natl Acad Sci U S A 2008; 105:9685-9690. (Pubitemid 352031361)
48. Aurora R, Donlin MJ, Cannon NA, Tavis JE. Genomewide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans. J Clin Invest 2009; 119:225-236.
49. Lara J, Xia GL, Purdy M, Khudyakov Y. Coevolution of the Hepatitis C Virus Polyprotein Sites in Patients on Combined Pegylated Interferon and Ribavirin Therapy. J Virol 2011; 85:3649-3663.
50. Lara J, Tavis JE, Donlin MJ, et al. Host-specific HCV evolution and response to the combined interferon and ribavirin therapy. Atlanta, GA: Bioinfomatics and Biomedicine Workshops (BIBMW) 2011; pp. 102-109.